Products

Latest News

View all
  • Phase 1/2 Trial Launches for Innovative Pancreatic Cancer Immunotherapy

    Phase 1/2 Trial Launches for Innovative Pancrea...

    UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...

    Phase 1/2 Trial Launches for Innovative Pancrea...

    UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...

  • FDA Approves NALIRIFOX as First-Line Treatment for Metastatic Pancreatic Cancer

    FDA Approves NALIRIFOX as First-Line Treatment ...

    New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...

    FDA Approves NALIRIFOX as First-Line Treatment ...

    New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...

  • Immunotherapy for Pancreatic Ductal Adenocarcinoma: Barriers and Opportunities

    Immunotherapy for Pancreatic Ductal Adenocarcin...

    Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...

    Immunotherapy for Pancreatic Ductal Adenocarcin...

    Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...

1 3
View all